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ABSTRACT 22 
We previously performed an siRNA screen and identified serum- and 23 
glucocorticoid-regulated kinase 1 (SGK1) as a host factor required for influenza A 24 
virus replication. However, the role of SGK1 in the influenza viral life cycle has 25 
never been examined. In this study, we demonstrate that SGK1 is required for 26 
optimal replication of influenza virus, using the SGK1 inhibitor GSK 650394 and 27 
SGK1-specific siRNAs. We also demonstrate that SGK1 is required for viral 28 
ribonucleoprotein nuclear export.  29 
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     Influenza A virus is an enveloped, negative-strand RNA virus that possesses 43 
eight RNA segments. It enters cells via receptor-mediated endocytosis. After 44 
internalization, the viral ribonucleoprotein complex (vRNP), composed of the viral 45 
RNA (vRNA), nucleoprotein (NP) and the polymerase proteins (PB1, PB2, PA), 46 
dissociates from the matrix protein (M1) and enters the nucleus, where vRNA 47 
replication and transcription occur (21). Newly synthesized vRNPs are exported 48 
from the nucleus through the chromosome region maintenance 1 protein 49 
(CRM1)-mediated pathway (26). Virus assembly is orchestrated by the M1 50 
protein, which interacts with viral membrane proteins hemagglutinin (HA), 51 
neuraminidase (NA), M2 ion channel protein, and vRNP complexes at the plasma 52 
membrane (2, 28). Virion release from the cell surface is facilitated by the 53 
neuraminidase activity of NA (21).  54 
     The role of cellular factors in the life cycle of influenza virus is not completely 55 
understood. We previously performed a genome-wide siRNA screen to identify 56 
host factors that are required for the replication of influenza A virus (15).  One of 57 
the 295 host factors that we identified in this screen is serum- and glucocorticoid-58 
regulated kinase 1 (SGK1), a serine/threonine kinase that is involved in a variety 59 
of processes including cellular stress response, cell growth and survival, renal 60 
sodium excretion, insulin secretion and neuronal excitability. SGK1 is ubiquitously 61 
expressed and is under transcriptional control of a variety of stimuli including cell 62 
shrinkage, glucocorticoids, mineralocorticoids and DNA damage. The localization 63 
of SGK1 depends on the functional state of the cell. Exposure of cells to serum 64 
leads to entry of SGK1 into the nucleus, whereas glucocorticoids enhance its 65 
localization into the cytosol (reviewed in 16). SGK1 phosphorylates several 66 
enzymes including the ubiquitin ligase Nedd4-2, SAPK/ERK kinase-1 (SEK1), 67 
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inducible nitric oxide synthase (iNOS) , glycogen synthase kinase 3 (GSK3), 68 
phosphomannomutase 2 and mitogen-activated protein kinase kinase kinase 3 69 
(MEKK3) (5, 12, 9, 27, 20, 3). SGK1 also regulates transcription factors including 70 
nuclear factor kappa B (NF-κB), cyclic AMP response element binding protein 71 
(CREB) and forkhead box O3a (FoxO3a) (17, 4, 6). Although the function of 72 
SGK1 in cellular processes is well-studied, its role in the life cycle of influenza 73 
virus has never been examined. Therefore, we sought to investigate the step(s) 74 
of the viral life cycle where SGK1 is involved. A better understanding of the role 75 
of host factors in the viral life cycle is important in discovering novel ways to 76 
combat the virus. 77 
     SGK1 is required for optimal replication of influenza virus. To determine 78 
whether SGK1 is important for replication of influenza A virus, we transfected 79 
each of two SGK1-specific siRNAs into a human lung adenocarcinoma cell line 80 
(A549), according to a previously published protocol (15). Briefly, A549 cells were 81 
transfected with SGK1 siRNA1 (GCGUUAGAGUGCCGCCUUAGA) or SGK1 82 
siRNA2 (UACAGGCUUAUUUGUAAUGUA). At 48 hours post-transfection, total 83 
RNA was prepared using Trizol and cDNA was synthesized using Superscript III 84 
First-Strand Synthesis System (Invitrogen). Real-time PCR was performed in a 85 
Roche LightCycler 480 II machine using previously published primers for SGK1 86 
(1).  As shown in Figure 1A, the levels of SGK1 mRNA were reduced to 32% and 87 
62% relative to the negative control siRNA, for cells that were transfected with 88 
SGK1 siRNA1 and siRNA2, respectively. To determine whether knockdown of 89 
SGK1 inhibits replication of influenza virus, another set of SGK1 siRNA1- or 90 
siRNA2-transfected A549 cells were infected with influenza virus (A/WSN/33) at 91 
an MOI of 0.01 at 48 hours post-transfection. Supernatants were harvested at 38 92 
hours post-infection (hpi) and plaque assay was performed to quantify the 93 
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amount of virus (Fig 1B). As a positive control, we transfected cells with an siRNA 94 
specific to NP. As a transfection control, we used an siRNA against RPS27A 95 
which leads to cell death upon successful transfection. The amount of virus in the 96 
NP siRNA-transfected cells was below the limits of detection of the assay. Cells 97 
that were transfected with the negative control siRNA had a viral titer of 2.9 × 107 98 
pfu/ml. The amount of virus in cells that were transfected with SGK1 siRNA1 and 99 
siRNA 2 were reduced to 4.6 × 105 pfu/ml and 3.0 × 105 pfu/ml, respectively (Fig. 100 
1B). We also confirmed that the knockdown of SGK1 by siRNA inhibited the 101 
replication of an H3N2 influenza virus (A/Wisconsin/05) (Figure 1C). These 102 
results indicate that SGK1 is required for optimal replication of influenza virus. 103 
      Next, we wanted to determine whether a compound that inhibits SGK1 can 104 
reduce viral replication. To this end, we tested GSK 650394, a commercially 105 
available compound that inhibits SGK1 and SGK2 with IC50 values of 62 nM and 106 
103 nM for SGK1 and SGK2, respectively (Tocris Bioscience, Ellisville, MO). 107 
First, we tested the effect of this compound on the viability of A549 cells by 108 
treating them with two-fold serial dilutions (0.78 to 100 μM) of GSK 650394. At 109 
24, 48, 72 and 96 hours post-treatment, cell viability was measured using the 110 
CellTiter-Glo assay (Promega) that measures the amount of ATP in cells. As 111 
negative controls, cells were treated with the solvent DMSO or left untreated. It is 112 
important to note that the amount of DMSO was kept the same for all dilutions of 113 
GSK 650394. The results were expressed as percentage of viability relative to 114 
the DMSO control (Fig. 1D).  The effect of GSK 650394 on cell viability was 115 
dose- and time-dependent. Cells had good viability (≥91% relative to the DMSO 116 
control) at 0.78 to 3.13 μM throughout the 96-hour period. At 6.25 to 50 μM, cell 117 
viability was good (≥75% relative to the DMSO control) up to 48 hours. Cells that 118 
were treated with 100 μM of the compound had poor viability (≤64% relative to 119 
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the DMSO control). To determine whether GSK 650394 inhibits influenza virus 120 
replication, A549 cells were pre-treated with the compound for 2 to 4 hours and 121 
infected with WSN at an MOI of 0.01. After virus inoculation, cells were again 122 
incubated with medium containing GSK 650394. Supernatants were harvested 123 
24 hpi and plaque assay was performed. The results were expressed relative to 124 
the DMSO control (Fig. 1E). Viral titers were reduced in a dose-dependent 125 
manner. The estimated IC50 for GSK 650394 is 3.59 μM which results in an SI of 126 
34.84. There were several concentrations of the compound that reduced viral 127 
titers significantly without adversely affecting cell viability at 24 hours post-128 
treatment. For instance, at 50 μM where the cell viability was 94%, the viral titer 129 
was reduced to 5.9% relative to the DMSO control. This demonstrates that the 130 
decrease in viral titer is not merely due to the cytotoxic effect of the compound. 131 
Although GSK 650394 also inhibits SGK2, it is unlikely that the reduction in viral 132 
titers caused by GSK 650394 is due to inhibition of SGK2 because SGK2-133 
specific siRNAs did not inhibit the WSN-Renilla reporter virus in our siRNA 134 
screening (15). Taken together, our results confirm that SGK1 is required for 135 
optimal replication of influenza virus.  136 
     GSK 650394 does not inhibit influenza virus entry, polymerase activity or 137 
expression of viral proteins. Having shown that SGK1 is important for influenza 138 
virus replication, we next wanted to determine the step(s) of the virus life cycle 139 
where SGK1 is involved. First, we tested whether GSK 650394 inhibits entry of 140 
influenza virus using a previously published protocol (15). Briefly, A549 cells were 141 
treated with GSK 650394 (12.5, 25 and 50 μM), or solvent DMSO for 2 to 4 hours 142 
prior to incubation with pseudoparticles bearing WSN-HA/NA proteins and 143 
encoding the Gaussia luciferase reporter gene. As a positive control, cells were 144 
also treated with diphyllin (2.1 μM), a compound previously shown to inhibit 145 
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influenza virus entry (15). After 18 hours, cells were washed several times and 146 
new medium was added. Gaussia luciferase activity was measured 24 hours 147 
after addition of medium.  As shown in Fig. 2A, diphyllin reduced viral entry to 148 
10% relative to the DMSO control, whereas GSK 650394 did not inhibit viral entry 149 
at any of the concentrations that were tested. 150 
     Next, we tested whether GSK 650394 inhibits the polymerase activity of 151 
influenza virus using a previously published mini-genome assay (11). Briefly, 152 
A549 cells were treated with GSK 650394 (12.5, 25 and 50 μM), or solvent 153 
DMSO. As a positive control, cells were also treated with A3 (20 μM), a 154 
compound previously shown to inhibit influenza virus polymerase function by 155 
acting on the pyrimidine synthesis pathway (11). The cells were transfected with 156 
plasmids expressing the influenza virus polymerase proteins (PB1, PB2, PA), NP 157 
and an influenza virus-specific firefly luciferase reporter. A Renilla luciferase 158 
plasmid under the control of an SV40 promoter was also transfected to normalize 159 
transfection efficiency. As shown in Fig. 2B, A3 reduced the viral polymerase 160 
activity to 12% relative to the DMSO control, whereas GSK 650394 did not inhibit 161 
the viral polymerase activity at any of the concentrations that were tested. 162 
     To determine whether GSK 650394 inhibits the expression of influenza viral 163 
proteins, A549 cells were treated with GSK 650394 (12.5, 25 and 50 μM), or 164 
solvent DMSO. Two hours after treatment, cells were infected with WSN at an 165 
MOI of 3. After virus inoculation, the compound was added back to the cells. At 3, 166 
5 and 7 hpi, cells were lysed with RIPA buffer. The lysates were denatured and 167 
loaded on a Biorad 4-20% Mini-Protean TGX Precast gel. The proteins were 168 
transferred to a PVDF membrane and Western blot was performed using 169 
monoclonal antibodies to influenza viral proteins. As shown in Fig. 2C, GSK 170 
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650394 did not inhibit the expression of PB1, NP, M1, M2 and HA proteins at any 171 
of the concentrations and time points that were tested.  172 
     GSK 650394 impairs the export of influenza vRNPs into the cytoplasm of 173 
A549 cells. To determine whether SGK1 is involved in the trafficking of influenza 174 
vRNPs, we tested whether GSK 650394 inhibits trafficking of the vRNPs. A549 175 
cells were pre-treated with two-fold serial dilutions of GSK 650394 (12.5, 25 and 176 
50 μM) or solvent DMSO for 2 hours. To synchronize infection, cells were pre-177 
chilled for 10 minutes, infected with WSN virus at an MOI of 10 on ice for 20 178 
minutes and incubated at 37°C for 30 minutes. Cells were washed three times 179 
and medium containing the compound was added back to the cells. At 5 and 7 180 
hpi, cells were fixed, permeabilized and stained with a monoclonal antibody 181 
against NP (HT103). The results for all 3 concentrations were similar so only the 182 
results for the highest concentration (50 μM) are shown (Fig. 3). At 5 hpi, the 183 
vRNP localization was predominantly nuclear for both DMSO- and GSK 650394-184 
treated cells (Fig. 3A). The percentages of nuclear accumulation for DMSO- and 185 
GSK 650394-treated cells were 90 ± 3 % and 92 ± 3 %, respectively (Fig. 3B). At 186 
7 hpi, the vRNP localization was predominantly cytoplasmic for DMSO-treated 187 
cells. In contrast, the vRNP localization was predominantly nuclear for GSK 188 
650394-treated cells (Fig. 3A). The percentages of nuclear accumulation for 189 
DMSO- and GSK 650394-treated cells were 12 ± 3 % and 90 ± 3%, respectively 190 
(Fig. 3B). These results strongly indicate that GSK 650394 impairs the export of 191 
influenza vRNPs into the cytoplasm of A549 cells. 192 
     SGK1-specific siRNAs impair the export of influenza vRNPs into the 193 
cytoplasm of A549 cells. To further confirm that SGK1 is important for influenza 194 
vRNP trafficking, we tested whether SGK1-specific siRNAs would also inhibit this 195 
process. A549 cells were transfected with SGK1-specific siRNAs or negative 196 
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control siRNA. At 48 hours post-transfection, cells were pre-chilled for 10 197 
minutes, infected with WSN virus at an MOI of 10 on ice for 20 minutes and 198 
incubated at 37°C for 30 minutes.  At 5 and 7 hpi, cells were fixed, permeabilized 199 
and stained with a monoclonal antibody against NP (HT103). At 5 hpi, the vRNP 200 
localization was predominantly nuclear for negative control siRNA-, SGK1 201 
siRNA1- and SGK1 siRNA2-treated cells (Fig. 4A). The percentages of nuclear 202 
accumulation for negative control siRNA-, SGK1 siRNA1- and SGK1 siRNA2-203 
treated cells were 94 ± 3 %, 96 ± 0.4 %, and 94 ± 2 %, respectively (Fig. 4B).  At 204 
7 hpi, the vRNP localization was predominantly cytoplasmic for negative control 205 
siRNA-treated cells (Fig. 4A). The percentage of nuclear accumulation for 206 
negative control siRNA-treated cells was 12 ± 3 %.  In contrast, the percentages 207 
of nuclear accumulation for SGK1 siRNA1- and SGK1 siRNA2-treated cells were 208 
75 ± 3 %, and 63 ± 5 %, respectively (Fig. 4B). These results suggest that SGK1-209 
specific siRNAs impair the export of influenza vRNPs into the cytoplasm of A549 210 
cells.  211 
We have shown in Fig. 3 that GSK 650394, a compound that inhibits SGK1 and 212 
SGK2, impairs influenza vRNP export. To rule out the possibility that SGK2 is 213 
involved in vRNP export, we also tested whether SGK2-specific siRNAs impair 214 
this process. As shown in Fig. 4A, the vRNP localization was similar for negative 215 
control siRNA, SGK2 siRNA1 (CAGGGCCAATGGGAACATCAA) and SGK2 216 
siRNA2 (GUGCAUUCCUGGGAUUUUCTT) at 5 hpi and 7 hpi. Taken together, 217 
these results suggest that SGK1 but not SGK2 is involved in influenza vRNP 218 
export. This is consistent with our previous findings which indicated that SGK2 is 219 
not important for optimal influenza virus replication (15). Although SGK2 shares 220 
80% identity with SGK1 in the catalytic domain, it differs from SGK1 in a number 221 
of respects. First, the SGK1 mRNA is widely expressed, whereas the SGK2 222 
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mRNA has a more restricted distribution, being highly expressed in kidney, liver 223 
and pancreas, and at lower levels, in the brain. Unlike SGK1, the levels of SGK2 224 
mRNA in fibroblasts are not induced by stimulation with serum. SGK2 is activated 225 
by 3-phosphoinositide-dependent protein kinase-1 (PDK1), albeit more slowly 226 
than SGK1. In contrast with SGK1, activation of SGK2 is only suppressed 227 
partially by inhibitors of phosphatidylinositol (PI) 3-kinase (14). At this time, it is 228 
not known whether these functional differences may explain the preference of 229 
influenza virus for SGK1. 230 
     GSK 650394 does not inhibit nuclear export of HIV Rev protein. To 231 
determine whether GSK 650394 inhibits general nuclear export, we tested its 232 
activity against HIV Rev, using a well-described nuclear export assay (10). 233 
Briefly, A549 cells were treated with GSK 650394 (50μM) or DMSO for 4 hours 234 
prior to transfection with a plasmid encoding HIV Rev-GFP containing a mutated, 235 
nonfunctional nuclear export signal (NES) (pRev(1.4)-GFP) or the same plasmid 236 
with a functional NES reinserted upstream of GFP (pRev(1.4)-Rev NES-GFP). 237 
The compound was added back to the cells at 5 hours post-transfection. The 238 
cells were fixed and permeabilized at 24 hours post-transfection. As a positive 239 
control, cells were treated with the nuclear export inhibitor, leptomycin B (10 nM) 240 
or methanol at 18 hours post-transfection. As shown in Fig. 5A, the nuclear 241 
export-defective Rev(1.4)-GFP was predominantly nuclear under all treatments. 242 
The percentages of nuclear accumulation in methanol-, leptomycin B-, DMSO-, 243 
and GSK 650394-treated cells were 96 ± 3 %, 97 ± 2 %, 96 ± 4 %, and 94 ± 1 %, 244 
respectively. Figures 5A and B show that Rev(1.4)-NES-GFP was predominantly 245 
cytoplasmic in methanol-treated cells (17 ± 16 % nuclear accumulation). 246 
However, when cells were treated with leptomycin B, Rev(1.4)-NES-GFP was 247 
predominantly nuclear (75 ± 8 % nuclear accumulation), consistent with previous 248 
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findings (10). When cells were treated with DMSO or GSK 650394, Rev(1.4)-249 
NES-GFP was predominantly cytoplasmic. The percentages of nuclear 250 
accumulation in DMSO- and GSK 650394-treated cells were 15 ± 6 % and 21 ± 9 251 
%, respectively.  These results show that GSK 650394 does not inhibit nuclear 252 
export of HIV Rev protein, indicating that this compound does not impair general 253 
nuclear export. Taken together with the results in Fig. 3, this suggests that GSK 254 
650394 impairs influenza vRNP export in a specific manner. 255 
 We also investigated the phosphorylation of SGK1 upon viral infection. For 256 
this purpose A549 cells were infected with WSN at an MOI of 3. After 8 hours, 257 
cells were lysed as previously described. Western blot was performed using a 258 
monoclonal antibody for phospho-S422 SGK1 (Abcam). As a positive control we 259 
used cells treated with dexamethasone [1μM] for 8 hours and insulin [300nM] for 260 
1 hour (8). Infection with WSN virus led to partial phosphorylation of S422 in 261 
SGK1 (Fig. 6), confirming its role during the influenza A virus life cycle.   262 
     In summary, we have demonstrated that SGK1 is required for optimal 263 
replication of influenza A virus in A549 cells by using a compound that inhibits 264 
SGK1 (GSK 650394) and by siRNA knockdown of SGK1. GSK 650394 was 265 
originally developed as a compound that inhibits androgen-stimulated growth of 266 
the prostate cancer cell line LNCaP. In the absence of androgens, GSK 650394 267 
was not toxic to LNCaP cells (25). However, GSK 650394 has not been tested in 268 
animal models of prostate cancer. Similarly, our results show that GSK 650394 269 
inhibits viral replication at concentrations that are not toxic to cells. Thus, SGK1 270 
inhibitors may serve as potential anti-influenza agents. Further studies need to 271 
be performed to design analogs of this compound to improve its pharmacokinetic 272 
properties for testing in animal models of influenza virus infection. It has already 273 
been shown that acetylsalicylic acid (an inhibitor of the cellular factor NF-κB) 274 
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inhibits replication of the highly pathogenic avian influenza virus strain FPV 275 
(H7N7) without selection of resistant variants in MDCK cells (19). Therefore the 276 
regulation of SGK1 might lead to the development of novel drugs to circumvent 277 
the problem of drug resistance. We have also demonstrated that the reduction in 278 
viral replication is due to impaired vRNP export. Previous studies have utilized 279 
several compounds to identify host factors that are involved in influenza vRNP 280 
export. The CRM1-specific export inhibitor leptomycin B was shown to inhibit 281 
influenza A vRNP export in MDCK cells (26). The MEK-specific inhibitor U0126 282 
impaired influenza A vRNP nuclear export in MDCK cells (22). In this study, we 283 
have identified SGK1 as another host factor that is required for influenza vRNP 284 
export. We have demonstrated this using an SGK1 inhibitor and two SGK1-285 
specific siRNAs. In contrast with leptomycin B, the SGK1 inhibitor GSK 650394 286 
does not inhibit the general cellular nuclear export machinery, suggesting that 287 
SGK1 is involved in a distinct pathway that regulates influenza vRNP export. 288 
SGK1 is phosphorylated at position 422 upon viral infection; however, the 289 
specific phosphorylation target of SGK1 in the context of the viral life cycle needs 290 
to be investigated further. Several influenza virus proteins involved in vRNP 291 
export are known to be phosphorylated, including NP (13), PB1 (18), PA (24), M1 292 
(7) and NS2 (23). Whether SGK1 phosphorylates any of these viral proteins or 293 
another host factor involved in the viral life cycle remains to be elucidated. Our 294 
study demonstrates a novel function of SGK1 in the life cycle of influenza A virus. 295 
This may be important in the development of new antiviral agents to circumvent 296 
the problem of drug resistance.  297 
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 420 
FIGURE LEGENDS 421 
Fig 1. SGK1 is required for optimal replication of influenza virus. (A) SGK1-422 
specific siRNAs decrease SGK1 expression level. A549 cells were transfected 423 
with each of two SGK1-specific siRNAs or a negative control siRNA from Qiagen. 424 
Total RNA was extracted from the cells at  48 hours post-transfection and 425 
quantitative RT-PCR was performed to determine the levels of SGK1. Statistical 426 
-18 
significance was determined using one-way ANOVA (p<0.0001). (B and C) 427 
SGK1-specific siRNAs reduce influenza virus replication. A549 cells were 428 
transfected with each of two SGK1-specific siRNAs, a negative control siRNA, 429 
RPS27A-specific siRNA or an influenza virus nucleoprotein-specific siRNA. 430 
Forty-eight hours post-transfection, cells were infected with influenza virus H1N1 431 
A/WSN/33 (B) or H3N2 A/Wisconsin/05 (C) at an MOI of 0.01 to allow multicycle 432 
replication. Supernatants were harvested at 38-40 hours post-infection (hpi) and 433 
plaque assay was performed. Statistical significance was determined using one-434 
way ANOVA (p<0.0001). (D) Effect of GSK 650394 on cell viability.  A549 cells 435 
were treated with two-fold serial dilutions of the SGK inhibitor GSK 650394, or 436 
solvent DMSO or left untreated (U). The amount of DMSO is the same for all the 437 
dilutions. Cell viability (expressed as percent of the DMSO control) was 438 
measured at 24, 48, 72 and 96 hours post-treatment using the Promega 439 
CellTiter-Glo assay. (E) Effect of GSK 650394 on virus growth. GSK 650394-440 
treated cells were infected with WSN at an MOI of 0.01. Supernatants were 441 
harvested 24 hpi and plaque assay was performed. Viral titer was expressed as 442 
percent of the DMSO control. 443 
 444 
Fig. 2. GSK 650394 does not inhibit influenza virus entry, polymerase 445 
activity or expression of viral proteins. (A) GSK 650394 does not inhibit entry 446 
of influenza virus. A549 cells were treated with GSK 650394 (12.5, 25 and 50 447 
μM), or solvent DMSO, or diphyllin as positive control. The cells were then 448 
incubated with pseudoparticles bearing influenza virus HA/NA proteins and 449 
encoding the Gaussia luciferase reporter gene. After 18 hours,  the cells were 450 
washed and medium was added. A luciferase assay was performed twenty-four  451 
hours after addition of medium. (B) GSK 650394 does not inhibit the polymerase 452 
activity of influenza virus.  A549 cells were treated with  GSK 650394 (12.5, 25 453 
-19 
and 50 μM), or solvent DMSO, or A3 as positive control. The cells were 454 
transfected with plasmids expressing influenza virus polymerase proteins (PB1, 455 
PB2, PA), NP,  and an influenza virus-specific firefly luciferase reporter. A Renilla 456 
luciferase plasmid was co-transfected to normalize transfection efficiency. Four 457 
hours post-transfection, medium was replaced with DMEM containing the above 458 
compounds. Twenty four hours post-transfection, cells were lysed and luciferase 459 
activity was measured. (C) GSK 650394 does not affect expression of influenza 460 
viral proteins.  A549 cells were treated with two-fold dilutions of GSK 650394 461 
(12.5, 25 or 50 μM), or solvent DMSO. Cells were infected with WSN at an MOI 462 
of 3. At 3, 5 and 7 hours post-infection, cells were washed and lysed using RIPA 463 
buffer.  Lysates were loaded onto an SDS-PAGE gel and Western blot was 464 
performed using CC11 (PB1), HT103 (NP), E10 (M1 and M2), and 9G9 (HA) 465 
monoclonal antibodies. An antibody against GAPDH was used as a loading 466 
control.  467 
 468 
Fig 3. GSK 650394 impairs the export of influenza vRNPs into the 469 
cytoplasm of A549 cells. (A) A549 cells were treated with two-fold dilutions of 470 
GSK 650394 (12.5 , 25 and 50 μM), or solvent DMSO. Only the 50 μM treatment 471 
is shown above. To synchronize infection, cells were pre-chilled for 10 minutes 472 
and infected with influenza virus (A/WSN/33) at an MOI of 10 on ice. At 5 and 7 473 
hours post-infection, cells were fixed, permeabilized and stained with a 474 
monoclonal antibody against NP. 4'-6-Diamidino-2-phenylindole (DAPI) was used 475 
for nuclear staining. Results shown are representative images. White and red 476 
arrows indicate cells with NP cytoplasmic and nuclear accumulation, respectively. 477 
(B) Quantification of the percentage of NP nuclear signal at 5 hpi and 7 hpi. 478 
Results shown are the average of 3 replicates for the experiment in (A). 479 
-20 
Approximately 80-100 cells were counted for each replicate. Statistical 480 
significance was determined using two-way ANOVA (p<0.001).    481 
 482 
Fig 4. SGK1-specific siRNAs impair the export of influenza vRNPs into the 483 
cytoplasm of A549 cells. (A) A549 cells were transfected with each of two 484 
SGK1-specific siRNAs, each of two SGK2-specific siRNAs, or a negative control 485 
siRNA. At 48 hours post-transfection, cells were pre-chilled for 10 minutes and 486 
infected with influenza virus (A/WSN/33) at an MOI of 10 on ice. At 5 and 7 hours 487 
post-infection, cells were fixed, permeabilized and stained with a monoclonal 488 
antibody against NP. DAPI was used for nuclear staining. Results shown are 489 
representative images. (B) Quantification of the percentage of NP nuclear signal 490 
at 5 hpi and 7 hpi for SGK1-specific siRNAs and negative control siRNA. Results 491 
shown are the average of 3 replicates. Approximately 80-100 cells were counted 492 
for each replicate. Statistical significance was determined using two-way ANOVA 493 
(p<0.001).    494 
 495 
Fig 5. GSK 650394 does not inhibit nuclear export of HIV Rev protein. (A) 496 
A549 cells were treated with GSK 650394 (50μM), or solvent DMSO. The cells 497 
were transfected with either a plasmid encoding HIV Rev-GFP containing a 498 
mutated, non-functional NES (pRev(1.4)-GFP) or the same plasmid with a 499 
functional NES reinserted upstream of GFP (pRev(1.4)-Rev NES-GFP). As a 500 
positive control, cells were also treated with leptomycin B (10 nM), or solvent 501 
methanol at 18 hours post-transfection. The cells were fixed, permeabilized and 502 
observed under a fluorescence microscope 24 hours post-transfection. DAPI was 503 
used for nuclear staining. Approximately 70-80 cells were counted for each 504 
treatment. The average percentages of rev(1.4)-GFP or rev(1.4)-NES-GFP 505 
nuclear accumulation are shown. Statistical significance was determined using 506 
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two-way ANOVA (p<0.001). (B) Representative images of cells that were 507 
transfected with rev(1.4)-NES-GFP are shown. White and red arrows indicate 508 
cells with rev(1.4)-NES-GFP cytoplasmic and nuclear accumulation, respectively. 509 
 510 
Fig 6. Influenza infection activates the phosphorylation of SGK1. A549 cells 511 
were infected with influenza A/WSN/33 virus at an MOI of 3 for 8 hrs (WSN), or 512 
treated with dexamethasone (8 hrs) and insulin (1 hr) (+), or left untreated (-). 513 
Cells were washed and lysed using RIPA buffer. Lysates were loaded onto an 514 
SDS-PAGE gel and Western blots were performed using a polyclonal anti-515 
influenza NS1, phospho-specific SGK1 and a monoclonal anti-histone 3 antibody 516 
as a loading control. An arrowhead indicates the band corresponding to pSGK1. 517 
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